CE Mark for a New Generation Drug-Eluting Stent
Published date : 21 May 2013
Article date : 21 May 2013
Pharmabiz hosts an article that focuses on device manufacturer Biosensors International's receipt of the CE Mark for the BioMatrix NeoFlex. The device is the newest addition to the BioMatrix group of drug-eluting stents and features an advanced stent delivery system, improving pushability, trackability and crossability. According to the article, the stent offers a lower lesion entry profile than its predecessor although it retains the same combination of abluminal biodegradable polymer coating, proprietary limus drug Biolimus A9 (BA9) and flexible platform.
Results from the final 5 year LEADERS data demonstrated that BioMatrix Flex significantly reduced the risk of clinical events in the very late phase and showed a significant reduction in very late stent thrombosis (VLST), compared with Cypher Select.
The BioMatrix NeoFlex will be rolled out in all CE Mark global markets over the coming months.
Source: Pharmabiz.com, 21 May 2013
